Currently, some monoclonal antibodies (mAbs) are being studied for chronic rhinosinusitis with nasal polyps (CRSwNP). Three anti-IL-5 mAb: mepolizumab, reslizumab and benralizumab, have been tested through randomized clinical trials. In this real-life study, we aimed to describe the nasal effects of a cohort of asthmatic adults treated with anti-IL-5 mAb.
We carried out an observational study in adults (≥18 years) on anti-IL-5 mAb treatment. Variables included ACT and SNOT-22 questionnaires, nasal polyps score, blood total IgE levels and blood eosinophil count.
Overall, 38 participants were included in the study; 19 patients received mepolizumab, 17 were treated with benralizumab and 2 patients were given reslizumab. There was a statistically significant difference in the ACT and SNOT-22 scores before and after mAb treatment. ACT score increased from 11.05 to 21.5 after treatment ( < 0.001). SNOT-22 decreased from 57 to 37.3 after treatment ( = 0.004). No statistically significant differences between mAb groups were observed regarding the ACT or the SNOT-22 ( = 0.775) response ( = 0.775). In addition, 60.53% of patients obtained a minimal clinically important difference (MCID) in SNOT-22.
A significant clinical response based on SNOT-22 score evolution after anti-IL-5 mAb treatment was observed. This study also demonstrated that blood eosinophil count, rather than serum total IgE levels, is the best predictor of asthma symptom improvement, which was assessed through the ACT and SNOT-22 questionnaires.